CA2901613C - Dual mek/pi3k inhibitors and therapeutic methods using the same - Google Patents

Dual mek/pi3k inhibitors and therapeutic methods using the same Download PDF

Info

Publication number
CA2901613C
CA2901613C CA2901613A CA2901613A CA2901613C CA 2901613 C CA2901613 C CA 2901613C CA 2901613 A CA2901613 A CA 2901613A CA 2901613 A CA2901613 A CA 2901613A CA 2901613 C CA2901613 C CA 2901613C
Authority
CA
Canada
Prior art keywords
mek
pi3k
compound
structural formula
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2901613A
Other languages
English (en)
French (fr)
Other versions
CA2901613A1 (en
Inventor
Brian D. Ross
Marcian VAN DORT
Christopher Whitehead
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Michigan System
Original Assignee
University of Michigan System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Michigan System filed Critical University of Michigan System
Publication of CA2901613A1 publication Critical patent/CA2901613A1/en
Application granted granted Critical
Publication of CA2901613C publication Critical patent/CA2901613C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2901613A 2013-03-13 2014-03-12 Dual mek/pi3k inhibitors and therapeutic methods using the same Active CA2901613C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361779462P 2013-03-13 2013-03-13
US61/779,462 2013-03-13
PCT/US2014/023860 WO2014164942A1 (en) 2013-03-13 2014-03-12 Dual mek/pi3k inhibitors and therapeutic methods using the same

Publications (2)

Publication Number Publication Date
CA2901613A1 CA2901613A1 (en) 2014-10-09
CA2901613C true CA2901613C (en) 2020-10-20

Family

ID=51659015

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2901613A Active CA2901613C (en) 2013-03-13 2014-03-12 Dual mek/pi3k inhibitors and therapeutic methods using the same

Country Status (6)

Country Link
US (1) US9611258B2 (enExample)
EP (1) EP2968345B1 (enExample)
JP (1) JP6315848B2 (enExample)
CN (1) CN105358156A (enExample)
CA (1) CA2901613C (enExample)
WO (1) WO2014164942A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3160513B1 (en) 2014-06-30 2020-02-12 Glykos Finland Oy Saccharide derivative of a toxic payload and antibody conjugates thereof
US9968604B2 (en) * 2015-04-16 2018-05-15 Chiesi Farmaceutici S.P.A. Chromene derivatives as phoshoinositide 3-kinases inhibitors
WO2017079746A2 (en) 2015-11-07 2017-05-11 Multivir Inc. Methods and compositions comprising tumor suppressor gene therapy and immune checkpoint blockade for the treatment of cancer
EP4086250B1 (en) 2016-07-06 2024-12-11 The Regents Of The University Of Michigan Multifunctional inhibitors of mek/pi3k and mtor/mek/pi3k biological pathways and therapeutic methods using the same
KR20190112263A (ko) 2016-12-12 2019-10-04 멀티비르 인코포레이티드 암 및 감염성 질환의 치료 및 예방을 위한 바이러스 유전자 치료요법 및 면역 체크포인트 억제제를 포함하는 방법 및 조성물
AU2018316175B2 (en) * 2017-08-11 2023-02-23 The Regents Of The University Of Michigan Inhibitors of MEK/PI3K, JAK/MEK, JAK/PI3K/mTOR and MEK/PI3K3k/mTOR biological pathways and methods for improving lymphatic uptake, bioavailability, and solubility of therapeutic compounds
WO2020036635A2 (en) 2018-03-19 2020-02-20 Multivir Inc. Methods and compositions comprising tumor suppressor gene therapy and cd122/cd132 agonists for the treatment of cancer
WO2021113644A1 (en) 2019-12-05 2021-06-10 Multivir Inc. Combinations comprising a cd8+ t cell enhancer, an immune checkpoint inhibitor and radiotherapy for targeted and abscopal effects for the treatment of cancer
AU2021206684B2 (en) * 2020-01-10 2024-01-18 Immuneering Corporation MEK inhibitors and therapeutic uses thereof
CN111135309B (zh) * 2020-01-15 2023-04-28 重庆大学 一种核壳结构的替拉扎明药物载体及其制备方法和应用
AR121078A1 (es) 2020-01-22 2022-04-13 Chugai Pharmaceutical Co Ltd Derivados de arilamida con actividad antitumoral
IL313653A (en) * 2022-01-06 2024-08-01 Immuneering Corp Immuno-oncology inhibitors of MEK and their therapeutic uses
WO2024102859A1 (en) * 2022-11-09 2024-05-16 Immuneering Corporation Mek immune oncology inhibitors and therapeutic uses thereof
WO2025010287A2 (en) * 2023-07-03 2025-01-09 Immuneering Corporation Mek immune oncology inhibitors and therapeutic uses thereof
WO2025114495A1 (en) * 2023-11-28 2025-06-05 Universität Basel Pi3k inhibitors and use thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3811775B2 (ja) * 2000-07-19 2006-08-23 ワーナー−ランバート カンパニー リミティド ライアビリティー カンパニー ４−ヨードフェニルアミノベンズヒドロキサム酸の酸素化エステル
AR059339A1 (es) * 2006-02-09 2008-03-26 Chugai Pharmaceutical Co Ltd Derivados de la cumarina para trastornos proliferativos de celulas, composicion farmaceutica y agente terapeutico que los contiene
WO2008032060A1 (en) * 2006-09-14 2008-03-20 Astrazeneca Ab 4-benzimidaz0lyl-6-m0rph0lin0-2-piperazinylpyrimidine derivatives as p13k and mtor inhibitors for the treatment of proliferative disorders
WO2008032033A1 (en) * 2006-09-14 2008-03-20 Astrazeneca Ab 4-benzimidazolyl-2-morpholino-6-piperazinylpyrimidine derivatives as pi3k and mtor inhibitors for the treatment of proliferative disorders
US8569378B2 (en) 2007-07-20 2013-10-29 Toshiyuki Sakai p27 protein inducer
JP2011515462A (ja) * 2008-03-27 2011-05-19 アウククランド ウニセルビセス リミテッド 置換されたピリミジン、及びトリアジン、並びに癌療法におけるこれらの使用
US20110105521A1 (en) * 2008-07-11 2011-05-05 Novartis Ag Combination of (a) a phosphoinositide 3-kinase inhibitor and (b) a modulator of ras/raf/mek pathway
TW201038567A (en) 2009-03-27 2010-11-01 Pathway Therapeutics Ltd Pyrimidinyl and 1,3,5-triazinyl benzimidazole sulfonamides and their use in cancer therapy
CA2767008C (en) 2009-07-07 2018-01-30 Pathway Therapeutics, Inc. Pyrimidinyl and 1,3,5-triazinyl benzimidazoles and their use in cancer therapy
US20110166191A1 (en) * 2010-01-07 2011-07-07 Shijun Zhang 3-(2-amino-ethyl)-5-(3-cyclohexyl-propylidene)-thiazolidine-2,4-dione and its derivatives as multiple signaling pathway inhibitors and for the treatment of cancer
GB201007227D0 (en) * 2010-04-30 2010-06-16 Univ Basel Piperazinotriazines
US9233125B2 (en) * 2010-12-14 2016-01-12 University Of Maryland, Baltimore Universal anti-tag chimeric antigen receptor-expressing T cells and methods of treating cancer

Also Published As

Publication number Publication date
EP2968345A4 (en) 2016-08-17
US9611258B2 (en) 2017-04-04
US20160002212A1 (en) 2016-01-07
EP2968345B1 (en) 2017-12-13
JP2016516702A (ja) 2016-06-09
EP2968345A1 (en) 2016-01-20
CA2901613A1 (en) 2014-10-09
CN105358156A (zh) 2016-02-24
JP6315848B2 (ja) 2018-04-25
WO2014164942A1 (en) 2014-10-09

Similar Documents

Publication Publication Date Title
CA2901613C (en) Dual mek/pi3k inhibitors and therapeutic methods using the same
EP2888265B1 (en) Bivalent inhibitors of iap proteins and therapeutic methods using the same
AU2021202619B2 (en) Multifunctional inhibitors of MEK/PI3K and mTOR/MEK/PI3K biological pathways and therapeutic methods using the same
US20110319362A1 (en) Stat3 ligands and therapeutic uses thereof
WO2011159685A2 (en) Inhibition of wdr5 interaction with its binding partners and therapeutic methods
CA2825306A1 (en) Bcl-2/bcl-xl inhibitors and therapeutic methods using the same
EP4460306A2 (en) Targeting swi/snf related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 4 (smarca4)
WO2013082017A1 (en) Cyclized peptidomimetic small molecule inhibitors of the wdr5 and mll1 interaction
AU2018316175B2 (en) Inhibitors of MEK/PI3K, JAK/MEK, JAK/PI3K/mTOR and MEK/PI3K3k/mTOR biological pathways and methods for improving lymphatic uptake, bioavailability, and solubility of therapeutic compounds
CA3072080C (en) Inhibitors of mek/pi3k, jak/mek, jak/pi3k/mtor and mek/pi3k/mtor biological pathways and methods for improving lymphatic uptake, bioavailability, and solubility of therapeutic compounds

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20181017

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 11TH ANNIV.) - STANDARD

Year of fee payment: 11

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250303

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20250311

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250311

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 12TH ANNIV.) - STANDARD

Year of fee payment: 12

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260310

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260310